Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04723563 · ClinicalTrials.gov registry record · Phase 4
Nebulized Heparin for the Treatment of COVID-19
A Phase 4 study of COVID-19 and Pneumonia, Viral, sponsored by Frederick Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04723563: Completed Phase 4 study of COVID-19 and Pneumonia, Viral, sponsored by Frederick Health.
NCT04723563 is a Phase 4 study of COVID-19 and Pneumonia, Viral that has completed, run by Frederick Health. The registered enrollment target is 50 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04723563, a Phase 4 study of COVID-19 and Pneumonia, Viral, has completed, sponsored by Frederick Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Randomized, placebo controlled study to determine if nebulized heparin may reduce the need for mechanical ventilation in hospitalized patients with the novel coronavirus, also known as COVID-19. This will be a part of a larger meta-trial.
Primary Outcome
proportion of patients needed mechanical ventilation by day 28
Conditions Studied
Interventions
- DRUG 0.9%sodium chloride
- DRUG Heparin
Study Locations (1)
Maryland
- Frederick Health Hospital - Frederick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-02-22 |
| Est. Completion | 2021-08-23 |
| Phase | Phase 4 |
What the finished NCT04723563 record still lists
NCT04723563 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which 0.9%sodium chloride is the first listed.
NCT04723563 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04723563 about?
NCT04723563 is a clinical study titled "Nebulized Heparin for the Treatment of COVID-19". Randomized, placebo controlled study to determine if nebulized heparin may reduce the need for mechanical ventilation in hospitalized patients with the novel coronavirus, also known as COVID-19. This will be a part of a larger meta-trial.
What is the current status of trial NCT04723563?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2021-02-22. Estimated completion is 2021-08-23.
What conditions does trial NCT04723563 study?
This clinical trial studies the following conditions: COVID-19, Pneumonia, Viral.
What interventions are being tested in trial NCT04723563?
The interventions under investigation include: 0.9%sodium chloride (DRUG), Heparin (DRUG).
Who is sponsoring clinical trial NCT04723563?
This trial is sponsored by Frederick Health, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04723563 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04723563's enrollment target sits among peer trials
50 245th of 298 higher than 50 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
RECRUITING · Phase 4
-
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
RECRUITING · Phase 4
-
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
COVID-19 Reactogenicity
ACTIVE NOT RECRUITING · Phase 4
-
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI